Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM
Caroline J. Coats,Ahmad Masri,Michael E. Nassif,Roberto Barriales-Villa, Michael Arad, Nuno Cardim,Lubna Choudhury,Brian Claggett,Hans-Dirk Duengen,Pablo Garcia-Pavia, Albert A. Hagege,James L. Januzzi,Matthew M. Y. Lee,Gregory D. Lewis,Chang-Sheng Ma,Martin S. Maron,Zi Michael Miao,Michelle Michels,Iacopo Olivotto, Artur Oreziak,Anjali T. Owens,John A. Spertus, Scott D. Solomon,Jacob Tfelt-Hansen, Marion van Sinttruije,Josef Veselka,Hugh Watkins,Daniel L. Jacoby,Polina German,Stephen B. Heitner,Stuart Kupfer,Justin D. Lutz,Fady I. Malik,Lisa Meng,Amy Wohltman,Theodore P. Abraham JOURNAL OF THE AMERICAN HEART ASSOCIATION（2024）
关键词
aficamten,cardiac myosin inhibitor,hypertrophic cardiomyopathy
AI 理解论文
溯源树
样例
